Kashmira S Chawla1, Cecilia Kanyama2, Abineli Mbewe2, Mitch Matoga2, Irving Hoffman3, Jonathan Ngoma4, Mina C Hosseinipour3. 1. UNC Project Malawi, Lilongwe, Malawi kashmira.chawla@gmail.com. 2. UNC Project Malawi, Lilongwe, Malawi. 3. UNC Project Malawi, Lilongwe, Malawi Division of Infectious Diseases, Department of Medicine, University of North Carolina Chapel Hill, NC USA. 4. Department of Medicine, Kamuzu Central Hospital, Lilongwe, Malawi.
Abstract
BACKGROUND: While previous research has provided evidence of the diagnostic accuracy of the GeneXpert MTB/RIF (GeneXpert), further information is needed about implementation in the real-world. This study evaluated the impact of the introduction of GeneXpert testing in a tertiary medical center according to the testing algorithm proposed by the National TB Control Program (NTP) guidelines. METHODS: All adult medicine inpatient persons with presumptive TB admitted between November 2013 and March 2014 were eligible for GeneXpert sputum testing and followed to TB treatment initiation status. RESULTS: We identified 932 persons with presumptive TB, of which 307 (32.9%) were GeneXpert tested. Those tested had an average age of 40 years, 49.2% (151) were male, 34.5% (106) were HIV positive, and 84.1% (249) presented with a cough. Of those GeneXpert tested, 28/307 (9.1%) tested positive, a 55.5% increase in detection compared to smear microscopy. However, the majority (44/72, 61%) of TB diagnoses were made by other modalities and not confirmed microbiologically. Of the 58 patients recommended to start treatment and discharged from the hospital, only 23 (40%) were documented to have started treatment at regional directly observed treatment short (DOTS) centers. CONCLUSIONS: GeneXpert contributed minimally to overall TB diagnosis and the cascade of care due to implementation challenges of sputum collection, empiric treatment, and weak linkage to care between inpatient and outpatient settings.
BACKGROUND: While previous research has provided evidence of the diagnostic accuracy of the GeneXpert MTB/RIF (GeneXpert), further information is needed about implementation in the real-world. This study evaluated the impact of the introduction of GeneXpert testing in a tertiary medical center according to the testing algorithm proposed by the National TB Control Program (NTP) guidelines. METHODS: All adult medicine inpatient persons with presumptive TB admitted between November 2013 and March 2014 were eligible for GeneXpert sputum testing and followed to TB treatment initiation status. RESULTS: We identified 932 persons with presumptive TB, of which 307 (32.9%) were GeneXpert tested. Those tested had an average age of 40 years, 49.2% (151) were male, 34.5% (106) were HIV positive, and 84.1% (249) presented with a cough. Of those GeneXpert tested, 28/307 (9.1%) tested positive, a 55.5% increase in detection compared to smear microscopy. However, the majority (44/72, 61%) of TB diagnoses were made by other modalities and not confirmed microbiologically. Of the 58 patients recommended to start treatment and discharged from the hospital, only 23 (40%) were documented to have started treatment at regional directly observed treatment short (DOTS) centers. CONCLUSIONS: GeneXpert contributed minimally to overall TB diagnosis and the cascade of care due to implementation challenges of sputum collection, empiric treatment, and weak linkage to care between inpatient and outpatient settings.
Authors: Sedona Sweeney; Carol Dayo Obure; Claudia B Maier; Robert Greener; Karl Dehne; Anna Vassall Journal: Sex Transm Infect Date: 2011-12-08 Impact factor: 3.519
Authors: A Akinkuotu; E Roemer; A Richardson; D C Namarika; C Munthali; A Bahling; I F Hoffman; M C Hosseinipour Journal: Int J STD AIDS Date: 2011-08 Impact factor: 1.359
Authors: Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla Journal: Lancet Infect Dis Date: 2013-03-24 Impact factor: 25.071
Authors: Jonathan G Peter; Grant Theron; Anil Pooran; Johnson Thomas; Mellissa Pascoe; Keertan Dheda Journal: Lancet Respir Med Date: 2013-07-19 Impact factor: 30.700
Authors: C T Kang'ombe; A D Harries; K Ito; T Clark; T E Nyirenda; W Aldis; P P Nunn; R D Semba; F M L Salaniponi Journal: Int J Tuberc Lung Dis Date: 2004-07 Impact factor: 2.373
Authors: Salla A Munro; Simon A Lewin; Helen J Smith; Mark E Engel; Atle Fretheim; Jimmy Volmink Journal: PLoS Med Date: 2007-07-24 Impact factor: 11.069
Authors: Shevin T Jacob; Patricia B Pavlinac; Lydia Nakiyingi; Patrick Banura; Jared M Baeten; Karen Morgan; Amalia Magaret; Yuka Manabe; Steven J Reynolds; W Conrad Liles; Anna Wald; Moses L Joloba; Harriet Mayanja-Kizza; W Michael Scheld Journal: PLoS One Date: 2013-08-05 Impact factor: 3.240
Authors: Bernhard Kerschberger; Michael Schomaker; Alex Telnov; Debrah Vambe; Nicholas Kisyeri; Welile Sikhondze; Lorraine Pasipamire; Siphiwe Mavis Ngwenya; Barbara Rusch; Iza Ciglenecki; Andrew Boulle Journal: Trop Med Int Health Date: 2019-08-07 Impact factor: 2.622
Authors: Daniel Kahn; Kara-Lee Pool; Linna Phiri; Florence Chibwana; Kristin Schwab; Levison Longwe; Ben Allan Banda; Khumbo Gama; Mayamiko Chimombo; Chifundo Chipungu; Jonathan Grotts; Alan Schooley; Risa M Hoffman Journal: Glob Health Sci Pract Date: 2020-03-31